Alfasigma is in an interesting situation. After Alfasigma makes a large investment to study Brilacidin for Ulcerative Proctitis, a possibility exists if the Brilacidin tablet is effective throughout the colon it may make any Brilacidin rectal application,suppository, enema or lavage obsolescent. In addition since the IBD market is so large there is a very real possibility the RFR and RNR owned by Alphasigma may be virtually useless; a large pharma companies with more assets could easily outbid it. The IBD market is enormous.

GLTA,Farrell


http://www.ipharminc.com/press-release/2019/7...igmoiditis

Forgive me I also posted this on the other board. Interested in insightful comments here.